January 2021 Simoa® Publications:
Neurology: Alzheimer’s and Parkinson’s Disease
Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage
Asken BM, et al.
Journal of Alzheimer’s Disease: JAD. 2021;78:265-276.
Alzheimer’s Disease
Early-Onset Alzheimer’s Disease: What Is Missing in Research?
Ayodele T, et al.
Curr Neurol Neurosci Rep. 2021;21:4.
Alzheimer’s Disease
Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease
Chatterjee P, et al.
Translational Psychiatry. 2021;11:27.
Alzheimer’s Disease
Population-based blood screening for preclinical Alzheimer’s disease in a British birth cohort at age 70
Keshavan A, et al.
Brain: A Journal of Neurology. 2021.
Alzheimer’s Disease
Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease
Moscoso A, et al.
JAMA Neurol. 2021.
Alzheimer’s Disease
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer’s disease
Simrén J, et al.
Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. 2021.
Alzheimer’s Disease
Trichostatin A ameliorates Alzheimer’s disease-related pathology and cognitive deficits by increasing albumin expression and Aβ clearance in APP/PS1 mice
Su Q, et al.
Alzheimers Res Ther. 2021;13:7.
Alzheimer’s Disease
The Potential of Neurofilament Light as a Biomarker in Alzheimer’s Disease
Xiong YL, et al.
Eur Neurol. 2021:1-10.
Alzheimer’s Disease
Association between polygenic risk score of Alzheimer’s disease and plasma phosphorylated tau in individuals from the Alzheimer’s Disease Neuroimaging Initiative
Zettergren A, et al.
Alzheimers Res Ther. 2021;13:17.
Alzheimer’s Disease
Parkinson’s disease with restless legs syndrome-an in vivo corneal confocal microscopy study
Andréasson M, et al.
NPJ Parkinsons Dis. 7, 4 (2021).
Parkinson’s Disease
January 2021 Simoa® Publications in Other Therapeutic Areas
